Letter: In-vitro detection of hypersensitivity to antituberculous drugs.
D000636:Aminosalicylic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D002464:Cell Migration Inhibition; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000276:immunology; D004359:Drug Therapy, Combination; D006801:Humans; D007111:Immunity, Cellular; D066298:In Vitro Techniques; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008264:Macrophages / Q000276:immunology; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014388:Tuberculosis, Lymph Node / Q000188:drug therapy; D014390:Tuberculosis, Meningeal / Q000188:drug therapy; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy; D014398:Tuberculosis, Renal / Q000188:drug therapy
D000636:Aminosalicylic Acids; D007538:Isoniazid; D012293:Rifampin